The role of 5-HT2C receptors in the antidepressant response: A critical review

Modern Trends in Pharmacopsychiatry

Volumn 27, Issue , 2010, Pages 155-181

  Martin, Cédric B P ^a   Hamon, Michel ^a   Lanfumey, Laurence ^a   Mongeau, Raymond ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; AGOMELATINE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; S 32006; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 63909;

AMYGDALOID NUCLEUS; ANXIETY DISORDER; BEHAVIOR; BRAIN; CENTRAL NERVOUS SYSTEM; CHRONIC STRESS; COMORBIDITY; DEPRESSION; DESENSITIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FORCED SWIMMING TEST; HORMONE RELEASE; HUMAN; HYPERTHERMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; MAJOR DEPRESSION; NERVE CELL; NEUROANATOMY; NONHUMAN; PANIC; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TAIL FLICK TEST; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE;

EID: 78649685750     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000319513     Document Type: Review

References (157)

1. 2 binding site after chronic administration of agonists and antagonists. Neuropharmacology 1986;25:1267-1271.
2. Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR: A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc Natl Acad Sci USA 1986;83:4086-4088.
3. 2-like receptor. Expression in brain, heart and intestine. FEBS Lett 1992;312:203-207.
4. Sharma A, Punhani T, Fone KC: Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5, 7-dihydroxytryptamine. Synapse 1997;27:45-56.
5. 2C receptor protein in the rat CNS. Neuropharmacology 2000;39:123-132.
6. 3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 2001;42:12-26.
7. Lopez-Gimenez JF, Tecott LH, Palacios JM, Mengod G, Vilaro MT: Serotonin 5-HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res 2002;67:69-85.
8. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993;231:223-229.
9. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-460.
10. 2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997;94:2036-2040.
11. 2C receptor. Psychopharmacology (Berl) 1996;126:234-240.
12. 2C receptor blockade. Psychopharmacology (Berl) 2005;177:448-458.
13. Bertaina-Anglade V, Drieu La Rochelle C, Boyer PA, Mocaer E: Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006;17:703-713.
14. Bakish D, Lapierre YD, Weinstein R, Klein J, Wiens A, Jones B, Horn E, Browne M, Bourget D, Blanchard A: Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993;13:409-414.
15. Ghaziuddin N, King CA, Welch KB, Zaccagnini J, Weidmer-Mikhail E, Mellow AM, Ghaziuddin M, Greden JF: Serotonin dysregulation in adolescents with major depression: hormone response to metachlorophenylpiperazine (mCPP) infusion. Psychiatry Res 2000;95:183-194.
16. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D: Modification of human 5-HT (2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 2004;9:55-64.
17. 2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 2001;6:579-585.
18. Massat I, Lerer B, Souery D, Blackwood D, Muir W, Kaneva R, Nothen MM, Oruc L, Papadimitriou GN, Dikeos D, Serretti A, Bellivier F, Golmard JL, Milanova V, Del Favero J, Van Broeckhoven C, Mendlewicz J: HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study. Mol Psychiatry 2007;12:797-798.
19. Moreau JL, Jenck F, Martin JR, Perrin S, Haefely WE: Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats. Psychopharmacology (Berl) 1993;110:140-144.
20. 2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology (Berl) 1996;123:346-352.
21. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Yadid G: Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005;48:34-42.
22. Strong PV, Greenwood BN, Fleshner M: The effects of the selective 5-HT (2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats. Psychopharmacology (Berl) 2009;203:665-675.
23. 2C antagonists: mechanistic studies. Neuropsychopharmacology 2007;32:1550-1557.
24. Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mork A, Honig G, Bogeso KP, Westerink BH, den Boer H, Wikstrom H V, Tecott LH: Inactivation of 5-HT (2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 2004;29:1782-1789.
25. 2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) 2008;199:549-568.
26. Cryan JF, Lucki I: Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine (2C) receptors. J Pharmacol Exp Ther 2000;295:1120-1126.
27. 2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl) 2007;192:159-170.
28. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998;286:913-924.
29. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG: Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996;30:17-30.
30. Gulley LR, Nemeroff CB: The neurobiological basis of mixed depression-anxiety states. J Clin Psychiatry 1993;54(Suppl): 16-19.
31. Ninan PT: The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999;60(Suppl 22):12-17.
32. Charney DS, Woods SW, Goodman WK, Heninger GR: Serotonin function in anxiety. 2. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24.
33. 2C receptor antagonist. Neuropharmacology 1997;36:609-620.
34. Pohl R, Yeragani VK, Balon R, Lycaki H: The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100-104.
35. Bristow LJ, O'Connor D, Watts R, Duxon MS, Hutson PH: Evidence for accelerated desensitisation of 5-HT (2C) receptors following combined treatment with fluoxetine and the 5-HT (1A) receptor antagonist, WAY 100, 635, in the rat. Neuropharmacology 2000;39:1222-1236.
36. 2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001;4:399-408.
37. Mongeau R, Martin C, Chevarin C, Maldonado R, Hamon M, Robledo P, Lanfumey L: 5-HT (2c) receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem 2010 Jul. 29 [Epub ahead of print].
38. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P: Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plusmaze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 1992;3:621-634.
39. Rezazadeh SM, Prather PL, Lal H: Sensitization to 5-HT1C receptor agonist in rats observed following withdrawal from chronic ethanol. Alcohol 1993;10:281-283.
40. 2C receptors but not by sympathomimetic effects. Neuropharmacology 1994;33:457-465.
41. Buczek Y, Tomkins DM, Higgins GA, Sellers EM: Dissociation of serotonergic regulation of anxiety and ethanol self-administration: a study with mCPP. Behav Pharmacol 1994;5:470-484.
42. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT: Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology (Berl) 1994;116:56-64.
43. Griebel G, Moreau JL, Jenck F, Mutel V, Martin JR, Misslin R: Evidence that tolerance to the anxiogenic-like effects of mCPP does not involve alteration in the function of 5-HT (2C) receptors in the rat choroid plexus. Behav Pharmacol 1994;5:642-645.
44. Gibson EL, Barnfield AM, Curzon G: Dissociation of effects of chronic diazepam treatment and withdrawal on hippocampal dialysate 5-HT and mCPP-induced anxiety in rats. Behav Pharmacol 1996;7:185-193.
45. Durand M, Mormede P, Chaouloff F: Wistar-Kyoto rats are sensitive to the hypolocomotor and anxiogenic effects of mCPP. Behav Pharmacol 2003;14:173-177.
46. Bert B, Felicio LF, Fink H, Nasello AG: The use of sudden darkness in mice: a behavioural and pharmacological approach. Psychopharmacology (Berl) 2005;179:846-853.
47. Nic Dhonnchadha BA, Bourin M, Hascoet M: Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 2003;140:203-214.
48. Mello Cruz AP, Pinheiro G, Alves SH, Ferreira G, Mendes M, Faria L, Macedo CE, Motta V, Landeira-Fernandez J: Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze. Psycho pharmacology (Berl) 2005;182:345-354.
49. Cornelio AM, Nunes-de-Souza RL: Anxiogenic-like effects of mCPP microinfusions into the amygdala (but not dorsal or ventral hippocampus) in mice exposed to elevated plus-maze. Behav Brain Res 2007;178:82-89.
50. 1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1261-1269.
51. 2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice. Behav Brain Res 2008;187:72-79.
52. Graeff FG: Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 2004;28:239-259.
53. Zangrossi H Jr, Viana MB, Graeff FG: Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino) tetralin in the elevated T-maze. Eur J Pharmacol 1999;369:267-270.
54. Cryan JF, Mombereau C, Vassout A: The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005;29:571-625.
55. Clenet F, De Vos A, Bourin M: Involvement of 5-HT (2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 2001;11:145-152.
56. 2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007;52:279-290.
57. Wetzler S, Asnis GM, DeLecuona JM, Kalus O: Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 1996;64:77-82.
58. Heisler LK, Pronchuk N, Nonogaki K, Zhou L, Raber J, Tung L, Yeo GS, O'Rahilly S, Colmers WF, Elmquist JK, Tecott LH: Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J Neurosci 2007;27:6956-6964.
59. Liposits Z, Phelix C, Paull WK: Synaptic interaction of serotonergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A light and electron microscopic immunocytochemical study. Histochemistry 1987;86:541-549.
60. Groenink L, Mos J, van der Gugten J, Olivier B: The 5-HT1A receptor is not involved in emotional stressinduced rises in stress hormones. Pharmacol Biochem Behav 1996;55:303-308.
61. Jorgensen H, Knigge U, Kjaer A, Vadsholt T, Warberg J: Serotonergic involvement in stressinduced ACTH release. Brain Res 1998;811:10-20.
62. Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH: Serotonin 5-HT (2C) receptors regulate anxiety-like behavior. Genes Brain Behav 2007;6:491-496.
63. Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF, Campeau S: Differential expression of 5HT-1A, alpha 1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, gamma-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J Comp Neurol 2004;474:364-378.
64. Boadle-Biber MC, Singh VB, Corley KC, Phan TH, Dilts RP: Evidence that corticotropin-releasing factor within the extended amygdala mediates the activation of tryptophan hydroxylase produced by sound stress in the rat. Brain Res 1993;628:105-114.
65. Meloni EG, Reedy CL, Cohen BM, Carlezon WA Jr: Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. Biol Psychiatry 2008;63:832-839.
66. Mo B, Feng N, Renner K, Forster G: Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors. Brain Res Bull 2008;76:493-498.
67. Liu R, Jolas T, Aghajanian G: Serotonin 5-HT2 receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 2000;873:34-55.
68. Boothman LJ, Sharp T: A role for midbrain raphe gamma aminobutyric acid neurons in 5-hydroxytryptamine feedback control. Neuroreport 2005;16:891-896.
69. 2C receptors in GABAergic cells of the anterior raphe nuclei. J Chem Neuroanat 2005;29:83-91.
70. Boothman L, Raley J, Denk F, Hirani E, Sharp T: In vivo evidence that 5-HT (2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 2006;149:861-869.
71. 2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharmacol 2003;139:998-1004.
72. Wright IK, Garratt JC, Marsden CA: Effects of a selective 5-HT2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br J Pharmacol 1990;99:221-222.
73. Queree P, Peters S, Sharp T: Further pharmacological characterization of 5-HT (2C) receptor agonistinduced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus in vivo. Br J Pharmacol 2009;158:1477-1485.
74. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas J P, Cistarelli L, Melon C, Millan MJ: Serotonin (2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 2000;36:205-221.
75. Ichikawa J, Kuroki T, Dai J, Meltzer HY: Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 1998;351:163-171.
76. Gobert A, Millan MJ: Serotonin (5-HT) 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 1999;38:315-317.
77. Boothman LJ, Mitchell SN, Sharp T: Investigation of the SSRI augmentation properties of 5-HT (2) receptor antagonists using in vivo microdialysis. Neuropharmacology 2006;50:726-732.
78. 2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 2005;30:2205-2215.
79. 2C receptors. J Neurochem 1995;64:2473-2479.
80. Stout BD, Clarke WP, Berg KA: Rapid desensitization of the serotonin (2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 2002;302:957-962.
81. Westphal RS, Backstrom JR, Sanders-Bush E: Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol Pharmacol 1995;48:200-205.
82. 2C receptor PDZ recognition motif prevents receptor phosphorylation and delays resensitization of receptor responses. J Biol Chem 2000;275:23620-23626.
83. Gavarini S, Becamel C, Altier C, Lory P, Poncet J, Wijnholds J, Bockaert J, Marin P: Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability. Mol Biol Cell 2006;17:4619-4631.
84. Schlag BD, Lou Z, Fennell M, Dunlop J: Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J Pharmacol Exp Ther 2004;310:865-870.
85. 2C receptors. Biol Psychiatry 1996;39:1000-1008.
86. Labrecque J, Fargin A, Bouvier M, Chidiac P, Dennis M: Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 1995;48:150-159.
87. Barker EL, Westphal RS, Schmidt D, Sanders-Bush E: Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 1994;269:11687-11690.
88. 2C receptors and their atypical regulation properties. Life Sci 2003;72:2429-2449.
89. Chanrion B, Mannoury La Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ: Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol 2008;73:748-757.
90. 2C receptors by chronic ligand exposure. Eur J Pharmacol 2004;498:59-69.
91. 2C receptor systems. Mol Pharmacol 1999;55:863-872.
92. 2C receptors. Brain Res Mol Brain Res 1997;48:45-52.
93. 2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 2006;171:355-362.
94. Peroutka SJ, Snyder SH: Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980;210:88-90.
95. 2C receptor levels in the rat. Br J Pharmacol 1998;123:1707-1715.
96. 2C receptors in the rat choroid plexus. Neuropsychopharmacology 1996;15:143-151.
97. 2C receptors after chronic treatment. Psychopharmacology (Berl) 2001;157:180-187.
98. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 1995;13:139-150.
99. 2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 2006;171:355-362.
100. Gleason SD, Lucaites VL, Shannon HE, Nelson DL, Leander JD: m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT (2C) receptors but not 5-HT (2A) or 5-HT (2B) receptors. Behav Pharmacol 2001;12:613-620.
101. 2C receptors in mice. Eur J Pharmacol 1998;341:135-138.
102. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA: Characterizing the effects of 5-HT (2C) receptor ligands on motor activity and feeding behaviour in 5-HT (2C) receptor knockout mice. Neuropharmacology 2009;57:259-267.
103. 2C receptors. Psychopharmacology (Berl) 1996;123:333-339.
104. Heisler LK, Tecott LH: A paradoxical locomotor response in serotonin 5-HT (2C) receptor mutant mice. J Neurosci 2000;20: RC71.
105. 2A/2C receptor antagonists. Psychopharmacology (Berl) 1997;130:144-151.
106. 2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008;149:1323-1328.
107. 2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. Eur J Pharmacol 1995;275:301-305.
108. Kimura Y, Naitou Y, Wanibuchi F, Yamaguchi T: 5-HT (2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats. Eur J Pharmacol 2008;589:157-162.
109. 1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or antidepressants. Psychopharmacology (Berl) 1991;105:219-224.
110. Kelly J P, Wrynn AS, Leonard BE: The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997;74:299-316.
111. 2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 2008;33:2398-2406.
112. Whitton P, Curzon G: Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology (Berl) 1990;100:138-140.
113. 2C receptor levels. Eur J Pharmacol 1994;262:125-131.
114. 2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 2001;41:186-199.
115. Mannoury LC, Chaput C, Touzard M, Millan MJ: An immunocapture/ scintillation proximity analysis of G alpha q/11 activation by native serotonin (5-HT) 2A receptors in rat cortex: blockade by clozapine and mirtazapine. Synapse 2009;63:95-105.
116. Rowland NE, Rokadia S, Green DJ, Robertson K: Relationship between anorexia and loss of serotonin uptake sites in brain of mice and rats receiving d-norfenfluramine or d-fenfluramine. Pharmacol Biochem Behav 2004;77:541-546.
117. Rowland NE, Robertson K, Green DJ: Effect of repeated administration of dexfenfluramine on feeding and brain Fos in mice. Physiol Behav 2003;78:295-301.
118. Melia KR, Ryabinin AE, Schroeder R, Bloom FE, Wilson MC: Induction and habituation of immediate early gene expression in rat brain by acute and repeated restraint stress. J Neurosci 1994;14:5929-5938.
119. Navailles S, Moison D, Cunningham KA, Spampinato U: Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology 2008;33:237-246.
120. Dremencov E, El Mansari M, Blier P: Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci 2009;34:223-229.
121. 2C receptor functions in mice. Eur Neuropsychopharmacol 2010;20(Suppl 1):544.
122. 2C receptor disrupts transactivation of the small G-protein RhoA. Mol Pharmacol 2004;65:252-256.
123. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C: Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002;34:349-356.
124. 2C receptor alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 2001;24:478-491.
125. Iwamoto K, Kato T: RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett 2003;346:169-172.
126. Gurevich I, Englander MT, Adlersberg M, Siegal NB, Schmauss C: Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J Neurosci 2002;22:10529-10532.
127. Englander MT, Dulawa SC, Bhansali P, Schmauss C: How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci 2005;25:648-651.
128. Abbas AI, Urban DJ, Jensen NH, Farrell MS, Kroeze WK, Mieczkowski P, Wang Z, Roth BL: Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method. Nucleic Acids Res 2010;38: e118.
129. Kawahara Y, Grimberg A, Teegarden S, Mombereau C, Liu S, Bale TL, Blendy JA, Nishikura K: Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 2008;28:12834-12844.
130. Olaghere da Silva UB, Morabito M V, Canal CE, Airey DC, Emeson RB, Sanders-Bush E: Impact of RNA editing on functions of the serotonin 2C receptor in vivo. Front Neurosci 2010;4:1-10.
131. 2C receptor isoforms. Pharmacogenomics J 2005;5:244-254.
132. Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH: Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 1994;151:1626-1630.
133. Giorgetti M, Tecott LH: Contributions of 5-HT (2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004;488:1-9.
134. 2C receptors, respectively. Neuropsychopharmacology 1995;13:1-8.
135. Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA, Dourish CT: Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 2000;130:1305-1314.
136. Yau JL, Olsson T, Noble J, Seckl JR: Serotonin receptor subtype gene expression in the hippocampus of aged rats following chronic amitriptyline treatment. Brain Res Mol Brain Res 1999;70:282-287.
137. Spurlock G, Buckland P, O'Donovan M, McGuffin P: Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology 1994;33:433-440.
138. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (Berl) 2003;167:274-280.
139. Freo U, Holloway H W, Greig NH, Soncrant TT: Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2 (di-N-propylamino) tetralin. Psychopharmacology (Berl) 1992;107:30-38.
140. Ulrichsen J, Partilla JS, Dax EM: Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion. Psychopharmacology (Berl) 1992;107:229-235.
141. 2C/2B receptor function. Neuropharmacology 1994;33:1581-1588.
142. Maj J, Bijak M, Dziedzicka-Wasylewska M, Rogoz R, Rogoz Z, Skuza G, Tokarski T: The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology (Berl) 1996;127:73-82.
143. 2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav 2004;78:683-689.
144. Maj J, Moryl E: Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol 1993;3:85-94.
145. Maj J, Moryl E: Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm Gen Sect 1992;88:143-156.
146. Kennedy AJ, Gibson EL, O'Connell MT, Curzon G: Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology (Berl) 1993;113:262-268.
147. Lucki I, Ward HR, Frazer A: Effect of 1-(m-chlorophenyl) piperazine and 1-(m-trifluoromethylphenyl) piperazine on locomotor activity. J Pharmacol Exp Ther 1989;249:155-164.
148. Benjamin J, Greenberg BD, Murphy DL: Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology (Berl) 1996;127:140-149.
149. Quested DJ, Sargent PA, Cowen PJ: SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology (Berl) 1997;133:305-308.
150. Wozniak KM, Aulakh CS, Hill JL, Murphy DL: Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments. Psychopharmacology (Berl) 1989;97:269-274.
151. Gudelsky GA, Koenig JI, Jackman H, Meltzer HY: Suppression of the hypo-and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors. Psychopharmacology (Berl) 1986;90:403-407.
152. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (Berl) 2003;167:274-280.
153. 2C receptor agonist, on intake of palatable food in mice. Pharmacol Biochem Behav 2008;91:176-180.
154. 2C receptor agonist WAY-161503. Brain Res 2006;1073-1074:240-251.
155. Li Q, Brownfield MS, Battaglia G, Cabrera TM, Levy AD, Rittenhouse PA, Van de Kar LD: Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2, 5-dimethoxy-4- iodophenyl)-2-aminopropane HCl (DOI). J Pharmacol Exp Ther 1993;266:836-844.
156. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 1996;6:169-175.
157. Wright IK, Heaton M, Upton N, Marsden CA: Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharmacology (Berl) 1992;107:405-414.